Article
Optovue has received FDA 510(k) clearance for an updated version of its proprietary spectral-domain optical coherence tomography system (RTVue XR FD-OCT system).
Fremont, CA-Optovue has received FDA 510(k) clearance for an updated version of its proprietary spectral-domain optical coherence tomography system (RTVue XR FD-OCT system).
The new version increases the number of A-scans per second to 70,000. It is scheduled to be available in the third quarter of this year.
“This FDA clearance affirms [the proprietary OCT system’s] position as the market leader, now with the fastest scan speed of any FDA-cleared device available,” said Jay Wei, Optovue chief executive officer. “We continue to leverage our experience in OCT product development and Fourier-domain technology to serve the needs of physicians and patients.”
For more articles in this issue of Ophthalmology Times eReport, click here.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.